Clinical Trials · NCT07564414
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 2,500
- Start date
- May 2026
- Locations
- 303 sites, 19 countries
- Primary endpoint
- Relative change in body weight